1. Introduction {#sec1-ijms-20-05084}
===============

Renal fibrosis is a central event in the progression of chronic kidney diseases (CKDs) that leads to end-stage kidney diseases \[[@B1-ijms-20-05084]\]. Among multiple mediators, transforming growth factor-β (TGF-β) is a key mediator that triggers activation of progressive renal fibrosis signaling pathways \[[@B1-ijms-20-05084],[@B2-ijms-20-05084]\]. These pleiotropic effects of TGF-β are mediated via three types of TGF-β receptors (TGFβRI, TGFβRII and TGFβRIII) that function as serine-threonine kinases. In a Smad-dependent pathway, TGF-β binds to TGFβRII, which binds and phosphorylates TGFβRI. These events trigger the recruitment of the receptor-regulated Smad proteins (R-Smads) Smad2 and Smad3 to the cytoplasmic domain of activated TGFβRI, which then phosphorylates Smad2/3. Once phosphorylated, Smad2/3 form a trimer with Smad4, which is then translocated to the nucleus where it binds to Smad-binding elements to modulate target genes \[[@B3-ijms-20-05084]\]. Targeting TGF-β/Smad signaling remains an attractive target for the development of therapeutics for fibrotic progression \[[@B4-ijms-20-05084]\].

PGC-1α is a master regulator of mitochondrial biogenesis \[[@B5-ijms-20-05084]\]. Mitochondria are a major energy source for cells, and the kidney requires a constant level of ATP to transport solutes along nephrons. Indeed, the expression of PGC-1α in the kidney overlaps in the proximal tubule and medullary thick ascending limb of Henle, where mitochondrial activity is high \[[@B6-ijms-20-05084]\]. Many studies have suggested that PGC-1α is an attractive candidate that plays a role in kidney chemoprevention by improving CKD \[[@B7-ijms-20-05084]\]. The expression of PGC-1α was significantly reduced in not only kidney biopsy specimens derived from CKD patients but also unilateral ureteral obstruction-, folic acid- and APOL1-induced fibrosis models \[[@B8-ijms-20-05084],[@B9-ijms-20-05084],[@B10-ijms-20-05084]\]. Proximal tubule-specific deletion of liver kinase B1 (*LKB1*), an upstream regulator of PGC-1α, resulted in augmented renal fibrosis \[[@B11-ijms-20-05084]\]. In addition, Notch1/HES1-mediated PGC-1α downregulation was reported, and tubule-specific PGC-1α overexpression in a Notch-induced fibrosis mouse model alleviated profibrotic gene expression and renal fibrosis \[[@B8-ijms-20-05084]\]. Taurine upregulated gene 1 (*Tug1*), a conserved long noncoding RNA, positively regulates PGC-1α, which has a *Tug1*-binding element in its upstream promoter, leading to increased PGC-1α transcriptional activity. In diabetic nephropathy (DN), podocyte-specific overexpression of *Tug1* improved low PGC-1α expression, and the direct interaction between *Tug1* and PGC-1α improved DN-related biochemical and histological features \[[@B12-ijms-20-05084]\]. However, the molecular basis by which PGC-1α regulates profibrotic gene expression and fibrotic signal pathway remains to be further elucidated.

In this study, we aimed to determine whether PGC-1α can regulate TGF-β/Smad signaling, a core pathway in fibrotic progression and, if so, what the regulatory mechanism of this effect is. We found that the overexpression of PGC-1α negatively regulated the expression of TGFβRI through the downregulation of TGFβRI due to PGC-1α-mediated *let-7b/c* upregulation.

2. Results {#sec2-ijms-20-05084}
==========

2.1. Downregulation of PGC-1α in UUO-Induced Kidney Injury and TGF-β-treated HK-2 Cells {#sec2dot1-ijms-20-05084}
---------------------------------------------------------------------------------------

To clarify the physiological involvement of PGC-1α in fibrotic progression, we analyzed the expression pattern of PGC-1α in unilateral ureteral obstruction (UUO)-induced kidney injury and TGF-β-treated HK-2 cells. As the left ureteral ligation was performed for 7 days (*n* = 8) and 14 days (*n* = 8), fibrotic progression was intensified. The expression of the fibrotic markers TGF-β (precursor form and mature form), fibronectin, and α-SMA increased gradually with fibrotic progression. The expression of E-cadherin, which is characteristic of epithelial cells, was reduced in the UUO kidney and accumulation of extracellular matrix protein (Col1a1 and Col3a1) was increased in the UUO kidney ([Figure 1](#ijms-20-05084-f001){ref-type="fig"}A and [Figure S1](#app1-ijms-20-05084){ref-type="app"}). Furthermore, the protein and mRNA levels of PGC-1α declined inversely with fibrotic progression ([Figure 1](#ijms-20-05084-f001){ref-type="fig"}B,C). Consistent with the reduction in PGC-1α in UUO kidneys, the protein expression of PGC-1α in HK-2 cells was lowest at the same time when the TGF-β-induced fibrotic progression peaked after one day ([Figure 2](#ijms-20-05084-f002){ref-type="fig"}A,B). The mRNA expression of PGC-1α was also decreased by TGF-β treatment ([Figure 2](#ijms-20-05084-f002){ref-type="fig"}C). These results suggest that PGC-1α is a target protein that responds to fibrotic stress.

2.2. Protective Effects of PGC-1α on TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) {#sec2dot2-ijms-20-05084}
------------------------------------------------------------------------------------------

To examine the role and molecular mechanism of PGC-1α in fibrotic progression, we used an HK-2 cell line stably overexpressing *human PGC-1α* (PGC-1α cells) \[[@B13-ijms-20-05084]\] and compared the expression patterns of fibrotic markers with those of mock cells following TGF-β treatment. Consistent with the data shown in [Figure 2](#ijms-20-05084-f002){ref-type="fig"}A, the protein expression of fibronectin, vimentin, and α-SMA in mock cells was increased by TGF-β treatment, while their expression in PGC-1α cells was significantly reduced. In particular, PGC-1α cells showed a marked increase in the expression of E-cadherin, which is characteristic of epithelial cells. In addition, the amount of E-cadherin in PGC-1α cells was much higher than that in mock cells, although E-cadherin levels were decreased by TGF-β treatment ([Figure 3](#ijms-20-05084-f003){ref-type="fig"}A). Alternatively, to confirm changes in EMT markers induced by PGC-1α, we performed immunofluorescence staining, with red fluorescence indicating PGC-1α and green fluorescence indicating α-SMA or E-cadherin. Green fluorescence indicating α-SMA was increased by TGF-β treatment in mock cells, but not PGC-1α cells. Green fluorescence indicating E-cadherin was also decreased in TGF-β-treated mock cells, but its high level in PGC-1α cells did not change much following TGF-β treatment ([Figure 3](#ijms-20-05084-f003){ref-type="fig"}B). The expression of Snail and Slug, a transcription factor that affects E-cadherin expression, in TGF-β-treated PGC-1α cells, was lower than that in TGF-β-treated mock cells ([Figure 3](#ijms-20-05084-f003){ref-type="fig"}C). These results confirmed that PGC-1α has an inhibitory effect on TGF-β-induced EMT.

2.3. Negative Regulation of TGF-β/Smad Signaling by PGC-1α {#sec2dot3-ijms-20-05084}
----------------------------------------------------------

We wondered what signal pathway is involved in the protective effect of PGC-1α on TGF-β-induced EMT. To address this question, we observed the activation of the canonical TGF-β/Smad signal pathway, which is a major signaling pathway in fibrotic progression. In mock cells, the phosphorylation of Smad2/3 rapidly increased after 15 min of treatment with TGF-β, while Smad2/3 phosphorylation was effectively inhibited in PGC-1α cells. Interestingly, the protein levels of TGFβRI, a molecule upstream of the activation of Smad2/3, were downregulated in PGC-1α cells. The protein expression of TGFβRII was not significantly changed in either mock or PGC-1α cells. To examine whether this decrease in the TGFβRI protein level by PGC-1α is regulated at the transcriptional or translational level, we examined time-dependent mRNA changes in both TGF-β-treated mock and PGC-1α cells. The increase of PGC-1α mRNA in PGC-1α cells caused a decrease in TGFβRI mRNA, and there was no significant effect on TGFβRII in in both TGF-β-treated mock and PGC-1α cells ([Figure 4](#ijms-20-05084-f004){ref-type="fig"}A--D). These results suggest that the downregulation of TGFβRI by PGC-1α is regulated at the transcriptional level.

2.4. PGC-1α-Specific TGFβRI Downregulation {#sec2dot4-ijms-20-05084}
------------------------------------------

To further investigate whether the downregulation of TGFβRI is specific to PGC-1α, PGC-1α siRNAs were used to knock down PGC-1α in HK-2 and PGC-1α cells. Knockdown of endogenous PGC-1α in HK-2 cells increased the expression of TGFβRI, but there was no change in TGFβRII expression by PGC-1α knockdown ([Figure 5](#ijms-20-05084-f005){ref-type="fig"}A). Knockdown of PGC-1α in PGC-1α cells restored the reduced expression level of TGFβRI but did not affect the TGFβRII expression level ([Figure 5](#ijms-20-05084-f005){ref-type="fig"}B). These results suggest that the downregulation of TGFβRI is specific to PGC-1α.

2.5. PGC-1α Regulates let-7b/c-Mediated TGFβRI Expression {#sec2dot5-ijms-20-05084}
---------------------------------------------------------

Next, we attempted to elucidate the mechanism by which PGC-1α regulates TGFβRI. We formed a hypothesis based on the following clues. First, this regulatory mechanism of PGC-1α must involve a protective effect against EMT. Second, PGC-1α selectively acts on TGFβRI but not TGFβRII to regulate the activation of Smad2/3, leading to its decreased expression. Third, the regulation of TGFβRI by PGC-1α is regulated at the transcriptional level rather than the translational level. Recent studies have reported that the let-7 family of microRNAs modulate the expression of TGFβRI by binding to the 3' untranslated region (UTR) of TGFβRI \[[@B14-ijms-20-05084],[@B15-ijms-20-05084]\]. Consistent with this, the level of *let-7b/c* was higher in PGC-1α cells than in mock cells, and when the PGC-1α level was decreased again, the level of *let-7b/c* was lower than that of the mock cells ([Figure 6](#ijms-20-05084-f006){ref-type="fig"}A--C). Knockdown of endogenous PGC-1α in HK-2 cells by a dose-dependent treatment with siPGC-1α also resulted in the dose-dependent downregulation of *let-7b/c* ([Figure 6](#ijms-20-05084-f006){ref-type="fig"}D--F). These results suggest that PGC-1α is involved in the regulation of *let-7b/c*-mediated TGFβRI expression and inhibits subsequent activation of the TGFβRI-mediated Smad2/3 signaling pathway, resulting in protection against EMT.

3. Discussion {#sec3-ijms-20-05084}
=============

Mitochondria are power players in kidney function, and their functions are fine-tuned through the modulation of their biogenesis, bioenergetics, dynamics and clearance from cells (mitophagy) \[[@B16-ijms-20-05084],[@B17-ijms-20-05084]\]. Mitochondrial dysfunction plays a crucial role in the pathogenesis of kidney disease and is involved in the physiological process of renal fibrosis \[[@B18-ijms-20-05084]\]. Indeed, transcriptional analysis of biopsy samples from CKD patients showed that the pathways associated with mitochondrial function are downregulated compared to those in healthy individuals \[[@B19-ijms-20-05084]\]. Therefore, attention has been focused on identifying mitochondrial targets as therapeutic agents to improve the mitochondrial dysfunction in CKD patients \[[@B20-ijms-20-05084]\]. We have demonstrated the protective effect of PGC-1α on EMT progression. The decreased expression of PGC-1α was observed in the UUO kidney and TGF-β-treated HK-2 cells, and TGF-β-induced EMT was inhibited in HK-2 cells overexpressing PGC-1α. These findings suggest PGC-1α as an important therapeutic target for CKD.

In this study, we proposed the PGC-1α-induced negative regulation of TGFβRI as a protective mechanism in TGF-β-treated EMT progression. This effect led to the subsequent regulation of the TGF-β/Smad signaling pathway. Interestingly, PGC-1α targeted only TGFβRI as a means to modulate TGF-β/Smad signaling. Research on TGFβRI has also been carried out in different fields \[[@B4-ijms-20-05084]\]. Galunisertib (LY2157299), an oral inhibitor of TGFβRI kinase, inhibited the phosphorylation of Smad2/3 in a liver fibrosis model, thereby suppressing the production and maturation of COL1A1 \[[@B21-ijms-20-05084]\]. The possible antifibrotic effects of galunisertib on liver fibrosis enable its application to kidney fibrotic diseases. As another example of research on TGFβRI in different fields, exercise-trained muscles were shown to release myokine, which is beneficial for CKD patients. In addition, a paper reported crosstalk between the muscle and kidney in muscle-specific PGC-1α-overexpressing mice, which mimicked the effects of strength training. Irisin acts to protect against kidney fibrosis by interfering with TGFβRI activation through binding to TGFβRII \[[@B22-ijms-20-05084],[@B23-ijms-20-05084]\]. As shown by our study, PGC-1α targets and regulates TGFβRI at the transcriptional level as well as TGFβRI downstream signaling.

Finally, we have shown the mechanism by which PGC-1α targets TGFβRI downregulation. PGC-1α regulated the expression of let-7b/c, miRNA for which the 3' UTR of TGFβRI contains a binding site. In addition, *let-7b/c* was shown to be expressed in a PGC-1α-dependent manner. The level of *let-7b/c* in PGC-1α cells was decreased by siRNA against PGC-1α. *Let-7b/c* is an isotype of the miRNA *lethal-7* (*let-7*) family. In humans, the *let-7* family is composed of nine mature miRNAs (*let-7a, let-7b, let-c, let-7d, let-7e, let-7f, let-7g, let-7i*, and *miR-98*) encoded by 12 different genes \[[@B24-ijms-20-05084]\]. *Let-7* family members play two major biological roles; these miRNAs act as essential regulators of terminal differentiation and as fundamental tumor suppressors \[[@B25-ijms-20-05084]\]. Recently, members of the *let-7* family were suggested to act as an antifibrotic miRNAs in CKD \[[@B26-ijms-20-05084],[@B27-ijms-20-05084]\]. TGF-β downregulated *let-7b* in rat proximal tubular epithelial cells (NRK52E) with the upregulation of TGFβRI, leading to fibrogenesis. Ectopic expression of *let-7b* inhibited Smad3 activity by upregulating TGFβRI expression \[[@B15-ijms-20-05084]\]. *Let-7* family members (*let-7b/c/d/g/i*) mRNAs were also downregulated in glomerular mesangial cells under diabetic conditions. The *Lin28b/let-7* pathway, which is driven by the *Lin28b* upregulation-induced repression of *let-7*, was shown to control TGF-β-induced collagen accumulation in DN \[[@B27-ijms-20-05084]\]. Lipoxins are endogenous lipid mediators that promote the resolution of inflammation and inhibit renal fibrosis \[[@B28-ijms-20-05084],[@B29-ijms-20-05084]\]. Lipoxin A4 (LXA~4~) attenuated renal fibrosis in a rat UUO model and TGF-β-treated HK-2 cells, which was associated with an increased expression of *let-7c* miRNA \[[@B14-ijms-20-05084]\]. As shown by bioinformatic analysis of the cohort of miRNAs regulated by LXA~4,~ TGFβRI and HMGA2 were implicated as targets of *let-7c*. The 3' UTRs of human TGFβRI and HMGA2 contain two and six predicted *let-7c*-binding sites, respectively. LXA4-mediated upregulation of *let-7c* suppressed the TGF-β signaling pathway members including TGFβRI \[[@B14-ijms-20-05084]\].

The protective mechanism of PGC-1α against EMT progression can be explained as follows. First, *let-7b/c* acts as a downstream effector of PGC-1α that is positively upregulated by the overexpression of PGC-1α. Second, PGC-1α-mediated *let-7b/c* upregulation effectively inhibits the upregulation of TGF-β-induced TGFβRI. Third, the downregulation of *let-7b/c*-mediated TGFβRI decreases TGF-β-induced Smad2/3 activation. Fourth, the inhibition of TGF-β/Smad signaling lowers the expression of EMT markers and transcription factors, decreasing EMT progression. In conclusion, this study suggests PGC-1α as a candidate for the targeting of TGF-β/Smad signaling. We have shown a novel targeting scheme by which the *let-7b/c*/TGFβRI/Smad2/3 axis is regulated by PGC-1α ([Figure 7](#ijms-20-05084-f007){ref-type="fig"}). However, limitations of this study exist as well. Renal fibrosis is characterized by tubulointerstitial fibrosis, and resident fibroblasts are key players in fibrosis \[[@B30-ijms-20-05084]\]. It may be possible that PGC-1α's protective effect on EMT progression is part of renal fibrosis. Renal inflammation also plays a central role in the initiation and progression of CKD by causing fibrosis \[[@B31-ijms-20-05084]\]. There are many reports that PGC-1α has an anti-inflammatory effect \[[@B32-ijms-20-05084],[@B33-ijms-20-05084]\]. Therefore, it is necessary to investigate whether the inhibition of progression to EMT by TGF-β treatment in PGC-1α cells is an indirect effect of inflammation modulation. Finally, further research is needed to determine whether the effects of PGC-1α will be equivalent to the effects of *NRF-1/2*, *ERRα,* and *PPARγ*, known as target transcription factors of PGC-1α \[[@B34-ijms-20-05084]\]. In vivo experiments using known pharmacological inducers of PGC-1α are necessary to determine the inhibitory effects of PGC-1α on EMT progression and the regulatory mechanisms of *let-7b/c*/TGFβRI/Smad2/3 axis \[[@B35-ijms-20-05084],[@B36-ijms-20-05084],[@B37-ijms-20-05084],[@B38-ijms-20-05084]\].

4. Materials and Methods {#sec4-ijms-20-05084}
========================

4.1. Reagents and Antibodies {#sec4dot1-ijms-20-05084}
----------------------------

Recombinant human TGF-β1 was purchased from R&D Systems (Minneapolis, MN, USA). Fugene HD transfection reagent was from Promega (Madison, WI, USA). Antibodies against PGC-1α and fibronectin were from Santa Cruz (Dallas, TX, USA) or Abcam (Cambridge, MA, USA). Antibodies against phospho-Stat3 (Tyr705), Total-Stat3, Total-Smad2/Smad3, Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425), TGF-β, Total-Jak2, and Phospho-Jak2 were all from Cell Signaling Technology (Danvers, MA, USA). E-cadherin was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Antibodies against α-SMA and β-actin were from Sigma-Aldrich (St. Louis, MO, USA). The selective antibiotics, zeocin was purchased from Invitrogen (Carlsbad, CA, USA).

4.2. UUO Model {#sec4dot2-ijms-20-05084}
--------------

The animal experiments were approved by the Animal Care Regulations (ACR) Committee of Chonnam National University Medical School (CNU IACUC-2016-50, date of approval 20 December 2016) and our protocols conformed to the institution guidelines for experimental animal care and use. Experiments were performed using male C57BL/6 mice (18 \~ 20 g, Samtako Bio Inc., Osan, Korea). Mice were housed under controlled temperature (21 ± 2 °C) in a 12 h light-dark cycle. Unilateral ureteral obstruction (UUO) was induced by ligation of the left ureter for one week (*n* = 8) or for two weeks (*n* = 8). The abdominal cavity was opened, and 2--0 silk ligature was placed at left proximal ureter under anesthesia with ketamine (50 mg/kg, intraperitoneally; Yuhan, Seoul, Korea). The control group for one week (*n* = 8) and two weeks (*n* = 8) received the same treatment, with the exception of the ligature.

4.3. Cell Culture and TGF-β Treatment {#sec4dot3-ijms-20-05084}
-------------------------------------

HK-2 cells (ATCC, Manassas, VA, USA), were cultured in complete DMEM-F12 media (WelGene, Daegu, Korea) supplemented with 10% fetal bovine serum, 50 U/mL penicillin and 50 μg/mL streptomycin at 37 °C under a humidified 5% CO~2~ atmosphere. Stably transfected HK-2 cells ectopically expressing indicated constructs (Mock and PGC-1α) were maintained in complete medium containing 200 µg/mL of zeocin (Invitrogen, Carlsbad, CA, USA) \[[@B13-ijms-20-05084]\]. For TGF-β treatment, cells were starved for one day with serum free media and treated with 10 ng/mL of TGF-β for the indicated time.

4.4. Transfection of siRNA {#sec4dot4-ijms-20-05084}
--------------------------

For knock-down of PGC-1α, PGC-1α siRNA (ON-TARGETplus SMARTpool, Dhamacon, Cat\# L-005111-00-0005) and control siRNA (ON-TARGETplus Non-targeting Control pool, Dhamacon, Cat\# D-001810-10-05) were transfected into HK-2 cells at 60% confluence using DhamaFect 1 solution at a final concentration of 10 or 30 nM for 24 h. Cells were starved for one day with serum free media and then stimulated with TGF-*β*1 as previously described.

4.5. Quantification of mRNA and miRNA {#sec4dot5-ijms-20-05084}
-------------------------------------

To quantify mRNA levels, total RNA was extracted from mouse kidney and HK-2 cells using TRIzol reagent (Invitrogen). cDNA was then reverse transcribed from 1 μg sample of total RNA using QuantiTect Reverse Transcription Kit (Qiagen Science, Germantown, MD, USA). Real-time PCR was performed using SYBR Green PCR master mix (Thermo Fisher Scientific, Austin, Texas, USA) and StepOnePlus Real-Time PCR System (Thermo Fisher Scientific, Austin, Texas, USA). Primer sequences for real-time PCR were as follows: hPGC-1α, forward, 5′-TCTCAGTACCCAGAACCATGCA-3′, reverse, 5′-GCTCCATGAATTCTCAGTCTTAACAA-3′; hGAPDH, forward, 5′- GACATCAAGAAGGTGGTGAA-3′, reverse, 5′- TGTCATACCAGGAAATGAGC-3′. hTGFβRI (Cat\# HP100487) and hTGFβRII (Cat\# HP100394) were purchased with Sino Biological Inc (Beijing, China). miRNA-enriched RNA was extracted from HK-2 cells using a miRNeasy RNA extraction kit Kit (Qiagen Science, Germantown, MD, USA). Total RNA containing miRNA (0.5 to 1 μg) was converted into cDNA using miScript II RT Kit Kit (Qiagen Science, Germantown, MD, USA). Real-time PCR was performed using miScript SYBR Green PCR Kit with *let-7b* (Hs_let-7b_1 miScript Primer Assay, Cat\# MS00003122)- or *let-7c* (Hs_let-7c_1 miScript Primer Assay, Cat\# MS00003129)-specific miScript Primer Assay and Universal Primer. The human RNU6B miScript Primer Assay was used as control miRNA.

4.6. Immunofluorescence (IF) Staining {#sec4dot6-ijms-20-05084}
-------------------------------------

The mock and PGC-1α cells were seed onto four well-cell culture slides (2 X 10^4^/well) and were proceed as mentioned previous. Cells were washed with phosphate-buffered saline (PBS) and were fixed in 4% paraformaldehyde for 10 min. Subsequently, cells were permeabilized with permeabilization buffer (0.5% Triton X-100 in PBS) and the slides were incubated with primary antibodies to α-SMA (1/1000 dilution), E-cadherin (1/50 dilution), and PGC-1α (1/300 dilution, Abcam Cat\# ab54481) in diluted with equilibration buffer (1% bovine serum albumin, 0.5% Triton X-100 in PBS) at 4 °C overnight. Following incubation with primary antibody, the cells were washed with equilibration buffer and incubated for 1 h at room temperature with anti-mouse-FITC (for α-SMA and E-cadherin), and anti-rabbit-Cy3 (For PGC-1α) conjugated secondary antibodies (Vector Lab, Burlingame, CA, USA). The nuclei were counterstained using SlowFade Gold antifade reagent with DAPI (Invitrogen, Carlsbad, California, USA). Images were captured using a confocal microscope (LSM 510; Carl Zeiss, Oberkochen, Germany). Image was magnified at 800×, Bar = 20 μm.

4.7. Statistical Analysis {#sec4dot7-ijms-20-05084}
-------------------------

Values are presented as mean ± standard deviation (S.D.). Between-group differences were measured using one-way ANOVA with post-hoc Tukey HSD (Honestly Significant Difference) analysis where appropriate. *p*-values \< 0.05 were considered as statistically significant. All experiments were performed at least three times or more.
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![Downregulation of PGC-1α in the unilateral ureteral obstruction (UUO)-induced fibrotic kidney. To assess the fibrotic progression in the left kidney during ureter obstruction, we analyzed the expression of fibrotic marker proteins (premature and mature forms of TGF-β, fibronectin, and α-SMA) and an epithelial marker protein (E-cadherin) (**A**). To assess the involvement of PGC-1α in fibrotic progression, we analyzed the protein (**B**) and mRNA (**C**) levels of PGC-1α in whole-kidney homogenates. Bar graphs of protein levels show mean PGC-1α/β-actin expression, as measured by densitometry, and bar graphs of mRNA levels show mean PGC-1α/GAPDH expression. **^\#^** *p* \< 0.05, day 7 and day 14 UUO kidney vs. control kidney.](ijms-20-05084-g001){#ijms-20-05084-f001}

![Downregulation of PGC-1α in TGF-β-treated HK-2 cells. HK-2 cells were exposed to TGF-β. The protein expression of epithelial-mesenchymal transition (EMT) markers (fibronectin, E-cadherin, vimentin, and α-SMA) (**A**) and PGC-1α (**B**) was analyzed by western blotting. Bar graphs show mean PGC-1α, fibronectin, E-cadherin, vimentin, and α-SMA/β-actin expression levels, as measured by densitometry. (**C**) The mRNA expression levels of PGC-1α in TGF-β-treated HK-2 cells were analyzed by real-time polymerase chain reaction (PCR). **^\#^** *p* \< 0.05, TGF-β-treated vs. untreated.](ijms-20-05084-g002){#ijms-20-05084-f002}

![Comparison of EMT phenotype in TGF-β-treated mock or PGC-1α HK-2 cells. To confirm the protective effect of PGC-1α on EMT, HK-2 cells stably overexpressing PGC-1α (PGC-1α cells) and mock cells were treated with TGF-β and compared. (**A**) The protein expression levels of PGC-1α (c-myc tagged) and EMT markers (fibronectin, E-cadherin, vimentin, and α-SMA). (**B**) Morphological changes in PGC-1α (red) and EMT markers (green, labeled E-cadherin and α-SMA) by immunofluorescence staining (original magnification, 800×; bar = 20 μm). (**C**) Effects of changes in transcription factors (Snail and Slug) on E-cadherin expression in both cell lines were compared. Bar graphs show mean PGC-1α (c-myc-tagged), fibronectin, E-cadherin, vimentin, and α-SMA/β-actin expression levels, as measured by densitometry. \* *p* \< 0.05, mock cells vs. PGC-1α cells at the indicated time (0, 1, 3, and 5 days).](ijms-20-05084-g003){#ijms-20-05084-f003}

![Inactivation of TGFβ/Smad signaling by PGC-1α. To identify signaling pathways related to the protective effect of PGC-1α on EMT, the regulation of canonical TGF-β/Smad signaling at the protein (**A**) or mRNA (**B**--**D**) levels was assessed in mock and PGC-1α cells at the indicated times (0, 15, 30, 60, and 120 min for protein levels or 0, 15, 30, and 60 min for mRNA levels) after TGF-β treatment. Protein expression and the activation of canonical TGF-β/Smad signaling components were analyzed by measuring Smad2 phosphorylation at Ser465/467 and Smad3 phosphorylation at Ser423/425. Total expression levels of Smad2/3, TGFβRI, and TGFβRII were evaluated with anti-Smad2/3, anti-TGFβRI, and TGFβRII antibodies, respectively. Bar graphs show mean ratios of the phosphorylated to total forms of Smad2/3, TGFβRI, and TGFβRII/β-actin, as measured by densitometry. The mRNA levels of PGC-1α, TGFβRI, and TGFβRII were analyzed by real-time PCR. Bar graphs show mean ratios of the indicated targets (PGC-1α, TGFβRI, and TGFβRII) to GAPDH, which was used as an internal reference. \* *p* \< 0.05, mock cells vs. PGC-1α cells at the indicated time.](ijms-20-05084-g004){#ijms-20-05084-f004}

![PGC-1α-specific TGFβRI regulation. To confirm whether TGFβRI modulation is PGC-1α-specific, PGC-1α was knocked down using PGC-1α siRNA (30 nM, Dharmacon) in HK-2 cells (**A**) and mock and PGC-1α cells (**B**). After 48 h of transfection, the cells were treated with TGF-β for 2 h, harvested and analyzed by western blotting with the indicated antibodies (against PGC-1α, TGFβRI, and TGFβRII). **^\#^** *p* \< 0.05, TGF-β-treated vs. untreated mock cells; \* *p* \< 0.05, untreated mock cells vs. PGC-1α cells; **^§^** *p* \< 0.05, TGF-β-treated mock cells vs. PGC-1α cells; ^†^ *p* \< 0.05, siCon vs. siPGC-1α treatment of untreated PGC-1α cells; ^‡^ *p* \< 0.05, siCon vs. siPGC-1α treatment of TGF-β-treated PGC-1α cells.](ijms-20-05084-g005){#ijms-20-05084-f005}

![Regulation of *let-7b/c* by PGC-1α. To examine the regulation of *let-7b/c* by PGC-1α, control siRNA- or PGC-1α siRNA-transfected mock and PGC-1α cells (**A**--**C**) and PGC-1α siRNA-transfected HK-2 cells (**D**--**F**) were prepared as described in the Materials and Methods section. The levels of *let-7b, let-7c* (target miRNA) and RUN6B (internal reference) were quantitatively analyzed by real-time PCR. The bar graph shows the relative ratio of *let-7b* or *let-7c* to RUN6B, with the value in untreated mock cells set to 1. \* *p* \< 0.05, untreated mock cells vs. PGC-1α cells; **^§^** *p* \< 0.05, TGF-β-treated mock cells vs. PGC-1α cells; **^†^** *p* \< 0.05, siCon vs. siPGC-1α treatment of untreated PGC-1α cells; **^‡^** *p* \< 0.05, siCon vs. siPGC-1α treatment of TGF-β-treated PGC-1α cells.](ijms-20-05084-g006){#ijms-20-05084-f006}

![Regulation of *let-7b/c*/TGFβRI/Smad2/3 axis by PGC-1α. Treatment of TGF-β in human proximal tubule epithelial cells lowers the expression of PGC-1α and negatively regulates the expression of its downstream miRNA, *let-7b/c*. Downregulation of *let-7b/c* increases the expression of TGFβRI, which induces phosphorylation of TGFβRI by TGF-β treatment and subsequently increases the activity of Smad2/3. As a result, the EMT-related gene expression is increased and the EMT progression proceeds. The targeting strategy of the *let-7b/c*/TGFβRI/Smad2/3 axis by overexpression of PGC-1a is proposed as one of the therapeutic targets that inhibits EMT progression.](ijms-20-05084-g007){#ijms-20-05084-f007}
